Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

被引：26

作者：

Lv, Huilai ^{[1
]}

Tian, Yang ^{[2
]}

Li, Jiachen ^{[1
]}

Huang, Chao ^{[1
]}

Sun, Bokang ^{[1
]}

Gai, Chunyue ^{[1
]}

Li, Zhenhua ^{[1
]}

Tian, Ziqiang ^{[1
]}

机构：

[1] Hebei Med Univ, Dept Thorac Surg, Hosp 4, Shijiazhuang, Peoples R China

[2] Hangzhou Hosp Tradit Chinese Med, Dept Thorac & Cardiac Surg, Hangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

esophageal squamous cell carcinoma; pathologic complete response; combination therapy; immune checkpoint inhibitors; sintilimab; PREOPERATIVE CHEMOTHERAPY; CANCER; CHEMORADIOTHERAPY; CISPLATIN; 5-FLUOROURACIL; CAMRELIZUMAB; RECURRENCE; DOCETAXEL; SURVIVAL; PLACEBO;

D O I：

10.3389/fonc.2022.864533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundNeoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) are the standard treatments in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Adding PD-1 inhibitor to the chemotherapy has shown significant clinical benefits in first-line treatment of advanced ESCC. This study evaluated the efficacy and safety of neoadjuvant sintilimab plus chemotherapy in patients with resectable locally advanced ESCC. MethodsThe clinical data of 96 patients with resectable locally advanced ESCC, treated with sintilimab plus chemotherapy followed by esophagectomy, were reviewed. The pathologic complete response (pCR) rate, major pathological response (MPR) rate, R0 resection rate, tumor downstaging, survival, and safety were retrospectively analyzed. ResultsPatients were between the ages of 43 and 78 years (interquartile range [IQR], 60-69 years). Forty (41.7%) were diagnosed with stage II ESCC, 52 (54.2%) with stage III, and 4 (4.2%) with stage IVA. Sixty-seven (69.8%) were male, and 84 (87.5%) patients had an ECOG PS of <= 1. Forty-eight (50.0%) patients received 3-4 cycles of the neoadjuvant treatment. Twenty-nine (30.2%) patients obtained pCR, and MPR was achieved in 60 (62.5%) patients. The R0 resection rate was 99%. Eighty (83.3%) patients achieved clinical downstaging, and 71 (74.0%) achieved pathological downstaging. The median follow-up was 8.9 months, and 1-year DFS rate was 95.2% (95% CI, 88.8%-100%). Grade 3-4 TRAEs occurred in 12 (12.5%) patients, and the incidence of grade 3-4 surgical complications was 2.1%. No deaths were reported. ConclusionThese real-world data revealed that neoadjuvant sintilimab plus chemotherapy could provide encouraging pCR with good tolerability for resectable locally advanced ESCC, and this regimen warrants further exploration in prospective clinical studies.

引用

页数：9

共 52 条

[41] Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer [J].

van Hagen, P. ;

Hulshof, M. C. C. M. ;

van Lanschot, J. J. B. ;

Steyerberg, E. W. ;

Henegouwen, M. I. van Berge ;

Wijnhoven, B. P. L. ;

Richel, D. J. ;

Nieuwenhuijzen, G. A. P. ;

Hospers, G. A. P. ;

Bonenkamp, J. J. ;

Cuesta, M. A. ;

Blaisse, R. J. B. ;

Busch, O. R. C. ;

ten Kate, F. J. W. ;

Creemers, G. -J. ;

Punt, C. J. A. ;

Plukker, J. T. M. ;

Verheul, H. M. W. ;

Bilgen, E. J. Spillenaar ;

van Dekken, H. ;

van der Sangen, M. J. C. ;

Rozema, T. ;

Biermann, K. ;

Beukema, J. C. ;

Piet, A. H. M. ;

van Rij, C. M. ;

Reinders, J. G. ;

Tilanus, H. W. ;

van der Gaast, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2074-2084

[42] Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma A Randomized Clinical Trial [J].

Wang, Hao ;

Tang, Han ;

Fang, Yong ;

Tan, Lijie ;

Yin, Jun ;

Shen, Yaxing ;

Zeng, Zhaochong ;

Zhu, Jiangyi ;

Hou, Yingyong ;

Du, Ming ;

Jiao, Jia ;

Jiang, Hongjing ;

Gong, Lei ;

Li, Zhigang ;

Liu, Jun ;

Xie, Deyao ;

Li, Wenfeng ;

Lian, Changhong ;

Zhao, Qiang ;

Chen, Chun ;

Zheng, Bin ;

Liao, Yongde ;

Li, Kuo ;

Li, Hecheng ;

Wu, Han ;

Dai, Liang ;

Chen, Ke-Neng .

JAMA SURGERY, 2021, 156 (05) :444-451

[43] Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study [J].

Wang, Wenzhong ;

Yi, Yang ;

Jia, Yinghui ;

Dong, Xiaoxin ;

Zhang, Junxia ;

Song, Xiaomeng ;

Song, Yan .

THORACIC CANCER, 2022, 13 (06) :824-831

[44] Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer [J].

Watanabe, Masayuki ;

Baba, Yoshifumi ;

Yoshida, Naoya ;

Ishimoto, Takatsugu ;

Nagai, Yohei ;

Iwatsuki, Masaaki ;

Iwagami, Shiro ;

Baba, Hideo .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) :2838-2844

[45] The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study [J].

Xing, Wenqun ;

Zhao, Lingdi ;

Zheng, Yan ;

Liu, Baoxing ;

Liu, Xianben ;

Li, Tiepeng ;

Zhang, Yong ;

Ma, Baozhen ;

Yang, Yonghao ;

Shang, Yiman ;

Fu, Xiaomin ;

Liang, Guanghui ;

Yuan, Dongfeng ;

Qu, Jinrong ;

Chai, Xiaofei ;

Zhang, He ;

Wang, Zibing ;

Lin, Hongwei ;

Liu, Liang ;

Ren, Xiubao ;

Zhang, Jiangong ;

Gao, Quanli .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[46] JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC) [J].

Xu, R-H. ;

Wang, F. ;

Cui, C. ;

Yao, J. ;

Zhang, Y. ;

Wang, G. ;

Feng, J. ;

Yang, S. ;

Fan, Y. ;

Shi, J. ;

Zhang, X. ;

Shen, L. ;

Shu, Y. ;

Wang, C. ;

Dai, T. ;

Mao, T. ;

Chen, L. ;

Guo, Z. ;

Liu, B. ;

Pan, H. .

ANNALS OF ONCOLOGY, 2021, 32 :S1041-S1041

[47] Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer (TD-NICE): A single arm, phase II study [J].

Yan, X. ;

Zhao, J. ;

Lei, J. ;

Duan, H. ;

Ni, Y. ;

Zhou, Y. ;

Wang, X. ;

Qi, H. ;

Liu, H. ;

Tian, F. ;

Lu, Q. ;

Sun, J. ;

Yang, E. ;

Zhong, D. ;

Wang, T. ;

Huang, L. ;

Wang, J. ;

Jiang, T. .

ANNALS OF ONCOLOGY, 2021, 32 :S1442-S1442

[48] Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma The NEOCRTEC5010 Randomized Clinical Trial [J].

Yang, Hong ;

Liu, Hui ;

Chen, Yuping ;

Zhu, Chengchu ;

Fang, Wentao ;

Yu, Zhentao ;

Mao, Weimin ;

Xiang, Jiaqing ;

Han, Yongtao ;

Chen, Zhijian ;

Yang, Haihua ;

Wang, Jiaming ;

Pang, Qingsong ;

Zheng, Xiao ;

Yang, Huanjun ;

Li, Tao ;

Zhang, Xu ;

Li, Qun ;

Wang, Geng ;

Chen, Baofu ;

Mao, Teng ;

Kong, Min ;

Guo, Xufeng ;

Lin, Ting ;

Liu, Mengzhong ;

Fu, Jianhua .

JAMA SURGERY, 2021, 156 (08) :721-729

[49] Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial [J].

Yang, Hong ;

Liu, Hui ;

Chen, Yuping ;

Zhu, Chengchu ;

Fang, Wentao ;

Yu, Zhentao ;

Mao, Weimin ;

Xiang, Jiaqing ;

Han, Yongtao ;

Chen, Zhijian ;

Yang, Haihua ;

Wang, Jiaming ;

Pang, Qingsong ;

Zheng, Xiao ;

Yang, Huanjun ;

Li, Tao ;

Lordick, Florian ;

D'Journo, Xavier Benoit ;

Cerfolio, Robert J. ;

Korst, Robert J. ;

Novoa, Nuria M. ;

Swanson, Scott J. ;

Brunelli, Alessandro ;

Ismail, Mahmoud ;

Fernando, Hiran C. ;

Zhang, Xu ;

Li, Qun ;

Wang, Geng ;

Chen, Baofu ;

Mao, Teng ;

Kong, Min ;

Guo, Xufeng ;

Lin, Ting ;

Liu, Mengzhong ;

Fu, Jianhua .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) :2796-+

[50] Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study [J].

Yang, Peng ;

Zhou, Xiao ;

Yang, Xuefeng ;

Wang, Yuefeng ;

Sun, Tao ;

Feng, Shiying ;

Ma, Xianyou .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)

← 1 2 3 4 5 6 →